Bristol-Myers Squibb Company
CAMK2D antisense oligonucleotides and uses thereof

Last updated:

Abstract:

The present disclosure relates to antisense oligonucleotides, which target CAMK2D mRNA in a cell, leading to reduced expression of CAMK2D protein. Reduction of CAMK2D protein expression is beneficial for the treatment of certain medical disorders, e.g., cardiovascular-related diseases or disorders.

Status:
Grant
Type:

Utility

Filling date:

21 Feb 2019

Issue date:

13 Jul 2021